Related Experiment Video
Updated: Sep 10, 2025

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
The broad-spectrum kayvirus phage disrupts biofilms formed by methicillin-resistant Staphylococcus aureus and
Sukanya Apiratwarrasakul1, Pathomporn Sresuwadjarey1, Nathita Phumthanakorn2
1Veterinary Diagnostic Center, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
Abstract:
The escalating global challenge of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus pseudintermedius (MRSP) demands innovative therapeutic approaches. This study comprehensively characterized Staphylococcus phage vB_SauM_VL14 (VL14), a virulent bacteriophage from the Herelleviridae family (Twortvirinae subfamily, Kayvirus genus) with a 141,584-bp linear double-stranded DNA genome. Genomic analysis confirmed that phage VL14 is strictly lytic, containing 224 ORFs and four tRNAs, without lysogenic, virulence, or antimicrobial resistance genes. Phage VL14 demonstrated a 30-min latent period with a burst size of 110 PFU. Host range analysis revealed broad activity, lysing 100 % of S. aureus and 60 % of S. pseudintermedius isolates, including methicillin-resistant strains. The phage achieved significant bacterial reductions and exhibited remarkable biofilm-disrupting capabilities, substantially reducing the biofilm mass and viable cell counts. These findings establish phage VL14 as a broad-spectrum lytic phage with potent bactericidal and biofilm-disrupting activity, supporting its potential as a therapeutic agent against multidrug-resistant Staphylococcus infections and warranting further evaluation in in vivo and clinical settings.
Insights
This study characterizes Staphylococcus phage VL14, a lytic bacteriophage effective against multidrug-resistant Staphylococcus aureus (MRSA) and Staphylococcus pseudintermedius (MRSP). Phage VL14 shows potent bactericidal and biofilm-disrupting activity, indicating therapeutic potential.
Area of Science:
- Microbiology
- Bacteriophage Therapy
- Antimicrobial Resistance
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus pseudintermedius (MRSP) pose significant global health threats.
- Novel therapeutic strategies are urgently needed to combat these multidrug-resistant pathogens.
Purpose of the Study:
- To comprehensively characterize Staphylococcus phage vB_SauM_VL14 (VL14) for its therapeutic potential.
- To evaluate the lytic activity, host range, and biofilm-disrupting capabilities of phage VL14.
Main Methods:
- Genomic analysis of phage VL14 to determine its genetic makeup and identify potential risks.
- Assessment of phage VL14's lytic properties, including latent period and burst size.
- Host range determination against clinical isolates of S. aureus and S. pseudintermedius.
- Evaluation of phage VL14's efficacy in reducing bacterial load and disrupting biofilms.
Main Results:
- Phage VL14 possesses a 141,584-bp dsDNA genome and is strictly lytic, lacking undesirable genes.
- It exhibits a short latent period (30 min) and a high burst size (110 PFU).
- Phage VL14 effectively lyses 100% of S. aureus and 60% of S. pseudintermedius isolates, including resistant strains, and significantly reduces bacterial counts and biofilm formation.
Conclusions:
- Phage VL14 is a broad-spectrum lytic bacteriophage with significant bactericidal and biofilm-disrupting properties.
- Its characteristics support its potential as a therapeutic agent against multidrug-resistant Staphylococcus infections.
- Further in vivo and clinical studies are warranted to validate its therapeutic efficacy.
Related Concept Videos
Biofilms
Lytic Cycle of Bacteriophages
Gene Regulation in Microbial Communities: Quorum Sensing
DNA Bacteriophages
Biological Methods for Microbial Control
Viral Replication: Lytic Cycle

